Watch FLNA. Know when insiders buy.
One email the day a filing lands. Free.
FLNA
FILANA THERAPEUTICS, INC.
0.70
−0.02 −2.78%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
51
WATCH · shorts 51
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $33.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$77.9MNET CASH —52W 0.70 – 4.64SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 · Mar 31 | — | — | — | −$11.2M | −$10.3M | — | -0.21 | −$8.9M | — | — | May 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$13.6M | −$12.5M | — | -0.26 | −$9.7M | $501K | −$10.2M | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$11.9M | −$10.8M | — | -0.22 | −$6.2M | $80K | −$6.3M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$45.4M | −$44.2M | −818.5% | -0.92 | −$4.9M | $0 | −$4.9M | Nov 12 |
| Q1 2025 · Mar 31 | — | — | — | −$24.6M | −$23.4M | −193.5% | -0.48 | −$11.3M | $0 | −$11.3M | May 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$29.5M | −$27.6M | — | -0.58 | −$61.3M | $57K | −$61.3M | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$30.6M | −$27.9M | — | -0.58 | −$18.3M | $17K | −$18.3M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$61.4M | $6.2M | — | 0.13 | −$18.2M | $29K | −$18.3M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$19.9M | $25M | — | -0.43 | −$19.1M | $0 | −$19.1M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$22.8M | −$20.9M | — | -0.50 | −$22.3M | $41K | −$22.4M | Mar 12 |
| Q3 2023 · Sep 30 | — | — | — | −$27.9M | −$25.7M | — | -0.61 | −$26.5M | $22K | −$26.6M | Nov 7 |
| Q2 2023 · Jun 30 | — | — | — | −$28.8M | −$26.4M | — | -0.63 | −$19.9M | −$6K | −$19.9M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$95.4M | −$91M | — | -1.88 | −$32.3M | $581K | −$32.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$141.4M | −$24.3M | — | -1.46 | −$116.9M | $103K | −$117M | — | — |
| FY2023 · to Dec 31 | — | — | −$106M | −$97.2M | — | -2.32 | −$82M | $414K | −$82.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$80M | −$76.2M | — | -1.90 | −$77.5M | $2.7M | −$80.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$32.9M | −$32.4M | — | -0.82 | −$30.2M | $22.2M | −$52.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$6.4M | −$6.3M | — | -0.24 | −$5.4M | — | — | — | — |
Every number comes from FILANA THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.